Performance of the high-sensitivity troponin assay in diagnosing acute myocardial infarction: systematic review and meta-analysis

Ayman Al-Saleh MD, Ashraf Alazzoni MD, Saleh Al Shalash MD, Chenglin Ye MSc, Lawrence Mbuagbaw MD MPH, Lehana Thabane PhD, Sanjit S. Jolly MD MSc

Abstract

Background: High-sensitivity cardiac troponin assays have been adopted by many clinical centres worldwide; however, clinicians are uncertain how to interpret the results. We sought to assess the utility of these assays in diagnosing acute myocardial infarction (MI).

Methods: We carried out a systematic review and meta-analysis of studies comparing high-sensitivity with conventional assays of cardiac troponin levels among adults with suspected acute MI in the emergency department. We searched MEDLINE, EMBASE and Cochrane databases up to April 2013 and used bivariable random-effects modelling to obtain summary parameters for diagnostic accuracy.

Results: We identified 9 studies that assessed the use of high-sensitivity troponin T assays (n = 9186 patients). The summary sensitivity of these tests in diagnosing acute MI at presentation to the emergency department was estimated to be 0.94 (95% confidence interval [CI] 0.89–0.97); for conventional tests, it was 0.72 (95% CI 0.63–0.79). The summary specificity was 0.73 (95% CI 0.64–0.81) for the high-sensitivity assay compared with 0.95 (95% CI 0.93–0.97) for the conventional assay. The differences in estimates of the summary sensitivity and specificity between the high-sensitivity and conventional assays were statistically significant (p < 0.01). The area under the curve was similar for both tests carried out 3–6 hours after presentation. Three studies assessed the use of high-sensitivity troponin I assays and showed similar results.

Interpretation: Used at presentation to the emergency department, the high-sensitivity cardiac troponin assay has improved sensitivity, but reduced specificity, compared with the conventional troponin assay. With repeated measurements over 6 hours, the area under the curve is similar for both tests, indicating that the major advantage of the high-sensitivity test is early diagnosis.

High-sensitivity troponin assays have greatly improved the analytical performance of conventional cardiac troponin T and I testing.1–3 These assays permit the measurement of cardiac troponin concentrations that are about one-tenth of those measurable with conventional assays.4 The detection level is close to the physiologic concentrations of these biomarkers; therefore, there is interest in using high-sensitivity assays to diagnose acute myocardial infarction (MI) accurately, possibly within 3 hours of admission. The ability to use the rate of change in troponin level to diagnose acute MI is also being investigated. Many institutions throughout Europe and North America have transitioned from using the conventional troponin T assay to the high-sensitivity troponin T assay with no technical issues; both assays are run using the same analyzer.6 However, the US Food and Drug Administration has yet to approve the use of the high-sensitivity assays. This is partly because of the need for more information about their diagnostic accuracy and risk stratification.7

One of the main challenges is the potential for overdiagnosis of acute coronary syndromes because of the increased sensitivity of the high-sensitivity troponin test. Our aim was to assess the use of this test as a diagnostic tool. The early and accurate detection of myocardial injury leads to potentially earlier diagnosis.
and treatment with effective antiplatelet and antithrombotic agents. Use of the high-sensitivity troponin assay expedites exclusion of myocardial injury in patients presenting to the emergency department with chest pain. However, an assay that is very sensitive but has low specificity may lead to unnecessary investigations. We aimed to conduct a systematic review of the literature and a meta-analysis comparing the sensitivity, specificity and summary receiver operating characteristic curves of high-sensitivity troponin assays with those of conventional troponin T and I assays and test for heterogeneity.

Methods

Search strategy
A comprehensive systematic search of MEDLINE (1946 to April 2013), EMBASE (1980 to April 2013) and the Cochrane Central Register of Controlled Trials was carried out to find studies that compared high-sensitivity testing with conventional troponin T or I assays and included patients presenting to the emergency department with chest pain and suspected acute MI. Studies were excluded if they were case reports; evaluated high-sensitivity troponin assay in patients with heart failure; or were mainly designed to assess the prognostic impact of high-sensitivity troponin assay. Studies were also excluded if they did not directly compare high-sensitivity with conventional troponin testing. We restricted our search to studies published in English, and we manually searched abstracts from American Heart Association, American College of Cardiology and European Society of Cardiology conferences for the past 2 years. The indexed search terms we used were: highly sensitive troponin, high sensitivity troponin, high sensitive troponin, hs- TnT, hs- cTnT and hs- Tnl. References listed in relevant articles were also reviewed for possible inclusion. Details of our search strategy are described in Appendix 1 (www.cmajopen.ca/content/2/3/E199/suppl/DC1).

Titles and abstracts were screened independently by 2 authors (A. Al-Saleh and A. Alazzoni) to ensure that they met the inclusion criteria (Figure 1). Agreement was estimated using the kappa statistic (κ = 0.80, 95% CI 0.59–1.00, p < 0.001 indicating substantial agreement according to Koch and Landis18,19). Full texts of the selected articles were then screened by both authors for inclusion in the review. All disagreements were resolved by consensus.

Risk of bias assessment
Assessment of risk of bias was performed using the Cochrane tool: Quality Assessment of Diagnostic Accuracy Studies (QUADAS).8 This tool encompasses the following criteria, which we followed: representative spectrum, acceptable reference standard, acceptable delay between tests, partial verification avoided, differential verification avoided, incorporation avoided, reference standard results blinded, index test results blinded, uninterpretable results reported, withdrawals explained and sponsoring precluded.

Statistical analysis
In reporting our results, we followed the preferred reporting items for systematic reviews and meta-analyses (PRISMA) criteria.18 The process we used to select studies is summarized in a flowchart (Figure 1). We calculated sensitivity and specificity from the extracted contingency tables and individual study estimates were plotted in receiver operating characteristic curves. Heterogeneity was quantified using the F test, calculated using the random-effect approach and expressed as a percentage of the total variation across studies that was thought to be due to heterogeneity and could not be explained by our model. The higher the percentage, the more heterogeneity.19,20 To obtain estimates of sensitivity and specificity, with corresponding 95% confidence intervals (CI), we used a bivariate random-effects model.21 Summary receiver operating characteristic curves were drawn, plotting individual studies as well as the summary estimate. We also conducted a head-to-head comparison of the sensitive and conventional tests in terms of the summary estimates of sensitivity and specificity using the bivariate random-effects model. A modified paired t-test 22 was used to compare the mean logit sensitivity and logit specificity of the high-sensitivity and conventional troponin T assays at presentation. The statistical software used for this analysis was R, version 2.12.1.

Results
The literature review yielded 1035 articles from MEDLINE and EMBASE and 88 articles from the Cochrane database. After screening and applying the inclusion and exclusion criteria, 50 articles were isolated. After further review of the 50 articles, we excluded 17 articles not directly comparing the high-sensitivity and conventional tests, 13 that assessed a different population, such as patients with heart failure and 8 reviews and editorials (Figure 1). The remaining 11 studies were included in our meta-analysis. The selected studies were published between 2009 and 2012. The 38 excluded articles are listed in Appendix 2 (www.cmajopen.ca/content/2/3/E199/suppl/DC1).

Study populations and definition of outcomes
The selected studies enrolled patients who presented to the emergency department with symptoms, such as chest pain, that were suggestive of acute MI. Patients underwent the usual initial clinical assessment that included history taking, physical examination and 12-lead electrocardiogram. Cardiac troponin level was measured at presentation and again 2–24 hours later. High-sensitivity assays were used to measure troponin T at presentation in 9 studies,9–17 (Table 1) and troponin I in 3 studies.9,23,24 The final diagnosis for each patient was determined by event adjudicators after they had reviewed all available medical records from the time of the patient’s arrival in the emergency department to the end of the follow-up period (Table 1).

Acute MI was defined in accordance with the 2007 ESC/ACCP/AHA guidelines25 in 9 studies.9–15,23,24 In brief, acute MI was diagnosed when the patient showed typical clinical signs of myocardial ischemia and evidence of myocardial necrosis. Myocardial necrosis was diagnosed on the basis of a rising or falling cardiac troponin pattern (> 20% or < 20%
compared with level at admission) with at least 1 value above
the 99th percentile and an imprecision of ≤ 10%. Similar but
earlier 2000 and 2001 American College of Cardiology guide-
lines were used in 2 studies.16,17

Methodologic quality of the selected studies
The QUADAS tool showed that the studies were generally
of high quality (Table 2). All studies used an acceptable ref-
erence standard test and delays between tests were appro-
priate. A second or third reference standard was not used to
verify diagnosis; thus, partial and differential verification
bias was avoided in all studies. Most of the studies addressed
the target population. Incorporation bias was not present in
any of the studies, as high-sensitivity troponin assay was not
incorporated in a composite reference standard. Blinding of
reference standard results was unclear in 5 studies and
blinding of the index test results was unclear in only
1 study. Explanation of withdrawals was unclear in 1 study.

Sponsoring was adequately precluded in 3 studies, but this
remained unclear in 4.

Sensitivity and specificity of the high-sensitivity
troponin T assay

At presentation
Based on data from the 9 studies9–17 that used the high-
sensitivity troponin T assay (cut-off point 14 ng/L) at presen-
tation to the emergency department (Table 3 and Figure 2),
the summary sensitivity was estimated to be 0.93 (95% CI
0.89–0.96) and the heterogeneity (F) was 32.53% (95% CI
0.00%–68.88%). The summary specificity for the assay was
estimated to be 0.74 (95% CI 0.66–0.81) and F was 32.35%
(95% CI 0.00%–68.79%).

Only 8 studies10–17 reported sensitivity and specificity for
both the high-sensitivity troponin T assay and the conven-
tional troponin T or I assay, allowing us to conduct a head-to-

---

**Figure 1:** Identification of studies comparing high-sensitivity testing with conventional testing of cardiac troponin
levels to diagnose myocardial infarction in the emergency department.
Table 1: Characteristics of the studies that compared the high-sensitivity troponin T assay or high-sensitivity troponin I assay with the conventional assay

<table>
<thead>
<tr>
<th>Study</th>
<th>Participants, no. (% male)</th>
<th>Funding</th>
<th>Design</th>
<th>Centre(s)</th>
<th>Timing of troponin measurement</th>
<th>Outcome, no. (%)</th>
<th>Follow-up period</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Troponin T</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reichlin et al. 2009⁹</td>
<td>718 (66)</td>
<td>Swiss Heart Foundation, University Hospital, Basel, Abbott, Roche, Siemens</td>
<td>Prospective</td>
<td>Multicentre: Switzerland, Italy and Spain</td>
<td>At presentation and 6–9 h later</td>
<td>MI 123 (17)</td>
<td>60 d</td>
</tr>
<tr>
<td>Christ et al. 2010⁹⁰</td>
<td>2340 (64)</td>
<td>Roche Diagnostics</td>
<td>Retrospective</td>
<td>Single centre: Germany</td>
<td>At presentation and about 6 h later</td>
<td>MI 20 (15)</td>
<td>2 wk</td>
</tr>
<tr>
<td>Aldous et al. 2011¹¹</td>
<td>332 (60)</td>
<td>National Heart Foundation of New Zealand, Christchurch Hospital, Roche Diagnostics</td>
<td>Prospective</td>
<td>Single centre: New Zealand</td>
<td>At presentation and 6–24 h later</td>
<td>MI 110 (33)</td>
<td>Not reported</td>
</tr>
<tr>
<td>Body et al. 2011¹²</td>
<td>703 (61)</td>
<td>Manchester NHS Foundation Trust, Roche Diagnostics</td>
<td>Prospective</td>
<td>Single centre: United Kingdom</td>
<td>At presentation and (at least) 12 h after onset of symptoms</td>
<td>MI 130 (18)</td>
<td>6 mo</td>
</tr>
<tr>
<td>Freund et al. 2011¹³</td>
<td>317 (65)</td>
<td>Université Pierre et Marie Curie-Paris 6, Roche Diagnostics</td>
<td>Prospective</td>
<td>3 centres: France</td>
<td>At presentation and 3–9 h later if clinically indicated</td>
<td>MI 45 (14)</td>
<td>30 d</td>
</tr>
<tr>
<td>Melki et al. 2011¹⁴</td>
<td>233 (67)</td>
<td>Stockholm County Council and Karolinska Institute, Swedish Heart and Lung Foundation, National Board of Health and Welfare, Roche Diagnostics</td>
<td>Prospective</td>
<td>Single centre: Sweden</td>
<td>At presentation and 9–12 h later</td>
<td>MI 114 (48)</td>
<td>Discharge from hospital</td>
</tr>
<tr>
<td>Reiter et al. 2011¹⁵</td>
<td>1098 (67)*</td>
<td>Swiss Heart Foundation, University Hospital, Basel, Abbott, Roche, Siemens</td>
<td>Prospective</td>
<td>Multicentre: Switzerland, Italy and Spain</td>
<td>At presentation and 6–9 h later</td>
<td>MI 159 (14)</td>
<td>90 d</td>
</tr>
<tr>
<td>Weber et al. 2011¹⁶</td>
<td>2506 (66)</td>
<td>Kerckhoff-Stiftung Foundation, Sanofi Aventis, Roche Diagnostics</td>
<td>Retrospective analysis of data from 2 acute coronary syndrome registries</td>
<td>Multicentre: Germany and Argentina</td>
<td>At presentation</td>
<td>MI 1082 (43)</td>
<td>6 mo</td>
</tr>
<tr>
<td>Aldous et al. 2012¹⁷</td>
<td>939 (59)</td>
<td>National Heart Foundation of New Zealand, Health Research Council of New Zealand, Roche Diagnostics</td>
<td>Prospective</td>
<td>Multicentre: 9 countries in the Asia-Pacific region</td>
<td>At presentation, 2 h and 6–12 h later</td>
<td>MI 205 (21)</td>
<td>1 yr</td>
</tr>
<tr>
<td><strong>Troponin I</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reichlin et al. 2009⁹</td>
<td>718 (66)</td>
<td>Swiss Heart Foundation, University Hospital, Basel, Abbott, Roche, Siemens</td>
<td>Prospective</td>
<td>Multicentre: Switzerland, Italy and Spain</td>
<td>At presentation and 6–9 h later</td>
<td>MI 123 (17)</td>
<td>60 d</td>
</tr>
<tr>
<td>Keller et al. 2009⁹⁴</td>
<td>1818 (66)</td>
<td>Not available</td>
<td>Prospective</td>
<td>Multicentre: Germany</td>
<td>At presentation and 3–6 h later</td>
<td>MI 413 (23)</td>
<td>30 d</td>
</tr>
<tr>
<td>Bhardwaj et al. 2011²³</td>
<td>318 (54)</td>
<td>Inverness Medical Innovations</td>
<td>Prospective</td>
<td>Multicentre: United States</td>
<td>At presentation and repeated if clinically indicated</td>
<td>ACS 62 (20)</td>
<td></td>
</tr>
</tbody>
</table>

Note: ACS = acute coronary syndrome, MI = myocardial infarction. *Older population (≥ 70 yr).
head comparison. Summary sensitivities were estimated to be 0.94 (95% CI 0.89–0.97) and 0.72 (95% CI 0.63–0.79) for the high-sensitivity troponin T assay and the conventional assay, respectively. The summary specificities were estimated to be 0.73 (95% CI 0.64–0.81) and 0.95 (95% CI 0.93–0.97), respectively. The differences between the high-sensitivity and conventional assays in terms of both summary sensitivity and specificity were statistically significant ($p < 0.01$).

The summary receiver operating characteristic curve shows that the 95% confidence region of the pair of summary measures estimated from the high-sensitivity troponin T test did not overlap with that estimated from the conventional troponin assay (Figure 3). Thus, these results suggest that the high-sensitivity troponin T test has significantly higher sensitivity, whereas the conventional test has significantly higher specificity.

Serial troponin measurement

Only two of the selected studies presented area under the curve levels for high-sensitivity troponin T assays 3 and 6 hours after presentation in the emergency department (Table 4). Reichlin and colleagues reported similar areas under the curve for high-sensitivity troponin T assays and conventional troponin assays at 3 and 6 hours. For the high-sensitivity test, area under the curve was 0.98 (95% CI 0.97–0.99) at 3 hours and 0.98 (95% CI 0.96–0.99) at 6 hours; for the conventional troponin assay, area under the curve was 0.97 (95% CI 0.94–1.00) at 3 hours and 0.98 (95% CI 0.96–0.99) at 6 hours. Reiter and associates reported similar results: for high-sensitivity troponin T assay, area under the curve was 0.97 (95% CI 0.94–0.99) at 3 hours and 0.96 (95% CI 0.92–0.99) at 6 hours; for conventional troponin assays, the area under the curve was 0.97 (95% CI 0.93–0.99) at 3 hours and 0.97 (95% CI 0.92–0.99) at 6 hours. In summary, given repeated measures over 6 hours from presentation, the areas under the curves for high-sensitivity troponin T and conventional troponin assays were similar.

### Sensitivity and specificity of the high-sensitivity troponin I assay

Different assays and cut-off points have been used for studies of high-sensitivity troponin I assays (Table 5). Using an ADVIA Centaur immunoassay system (Siemens, Erlangen, Germany) to test for troponin I (cut-off point 40 ng/L), Reichlin and colleagues found the sensitivity and specificity to be 0.89 and 0.92 compared with 0.72 and 0.97, respectively, for the conventional assay. The Architect assay (Abbott Laboratories, Abbott Park, Ill.; cut-off point 28 ng/L) yielded a sensitivity of 0.86 and a specificity of 0.92; the Roche Troponin I assay (Roche, Basel, Switzerland; cut-off point 160 ng/L) yielded a sensitivity of 0.84 and a specificity of 0.94. On the other hand, using an Erenna Immunoassay System (Singulex,
Alameda, Cal.; cut-off point 6.28 ng/L), Bhardwaj and colleagues reported a sensitivity of 0.57 and a specificity of 0.86 compared with 0.22 and 0.97, respectively, for the conventional assay. Given the heterogeneous findings of different high-sensitivity troponin I assays, it is not possible to combine the results. It appears that the Architect (Abbott) and ADVIA Centaur (Siemens) high-sensitivity troponin I assays have lower sensitivity but improved specificity compared with high-sensitivity troponin T assays.

**Interpretation**

Our meta-analysis shows that the use of the high-sensitivity troponin assay to diagnose acute MI at presentation to the emergency department resulted in a significantly higher sensitivity compared with the conventional assay, although with reduced specificity. However, the areas under the receiver operating characteristic curves (an effective way to summarize the overall accuracy of diagnostic tests) for repeated measurements over 6 hours were similar for the 2 tests. Thus, the major advantage of the high-sensitivity troponin assay is early diagnosis and treatment of non-ST elevation MI.

The heterogeneity in our meta-analysis was in the low to moderate range: $I^2$ was 32.53% for sensitivity and 32.35% for specificity. This is explained by the use of different conventional troponin assays with different cut-off values as comparators.

**Explanation and comparison with other studies**

This review and meta-analysis comparing sensitivity and specificity of the high-sensitivity troponin assay with standard troponin assays among patients presenting with chest pain is important to clinicians whose institution adopts the high-sensitivity troponin assay. A prognosis-based systematic review of the high-sensitivity assay showed that, among patients presenting with chest pain who had a negative con-

<table>
<thead>
<tr>
<th>Study</th>
<th>High-sensitivity troponin T assay*</th>
<th>Conventional troponin assay</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Assay</td>
<td>Sensitivity</td>
</tr>
<tr>
<td>Reichlin et al. 2009</td>
<td>Elecsys 2010 (Roche Diagnostics)</td>
<td>0.95</td>
</tr>
<tr>
<td>Christ et al. 2010</td>
<td>Elecsys 2010 (Roche Diagnostics)</td>
<td>0.95</td>
</tr>
<tr>
<td>Aldous et al. 2011</td>
<td>Elecsys (Roche Diagnostics)</td>
<td>0.84</td>
</tr>
<tr>
<td>Body et al. 2011</td>
<td>Roche</td>
<td>0.85</td>
</tr>
<tr>
<td>Freund et al. 2011</td>
<td>Elecsys 2010 (Roche Diagnostics)</td>
<td>0.93</td>
</tr>
<tr>
<td>Melki et al. 2011</td>
<td>Roche Diagnostics</td>
<td>0.97</td>
</tr>
<tr>
<td>Reiter et al. 2011</td>
<td>Elecsys 2010 (Roche Diagnostics)</td>
<td>0.98</td>
</tr>
<tr>
<td>Weber et al. 2011</td>
<td>Elecsys (Roche Diagnostics)</td>
<td>0.96</td>
</tr>
<tr>
<td>Aldous et al. 2012</td>
<td>Elecsys (Roche Diagnostics)</td>
<td>0.88</td>
</tr>
</tbody>
</table>

Note: NA = not available, NPV = negative predictive value, PPV = positive predictive value.

*Cut-off point 14 ng/L.
Conventional assay but a positive high-sensitivity troponin assay, mortality was significantly higher than if both assays were negative. In that study, nearly a third of patients presenting with chest pain had a positive high-sensitivity troponin assay but a negative conventional assay. Although this suggests a higher rate of diagnosis of acute MI when the high-sensitivity assay was used instead of a conventional assay, this was associated with an adverse prognosis. Further data are needed to determine the effect of use of the high-sensitivity assay on outcomes and costs in the treatment of patients with suspected acute MI.

Another issue to consider is whether serial measurement of cardiac troponin level can enhance diagnosis of acute MI. This can involve measuring the high-sensitivity troponin at presentation to hospital and 1 or 2 hours later. Then diagnosis of acute MI might be made using initial result and amount of increase over the first couple of hours (relative to first result as a percentage or absolute change in troponin level). When the high-sensitivity troponin assay is used, large relative changes may occur despite minor absolute level increases, which is partly due to the ability of the sensitive troponin assay to detect troponin levels as low as the normal range. In a study of the absolute and relative changes in troponin levels at presentation and after 1 and 2 hours, absolute changes measured using the high-sensitivity troponin T assay had significantly greater diagnostic accuracy than relative changes. Despite the increased sensitivity of this assay at presentation, guideline committees have been reluctant to endorse its use to rule out acute MI based on a single value. In an investigation of an algorithm designed to expedite discharge of patients presenting to the emergency department with chest pain, acute MI was ruled out among patients with troponin T below 12 ng/L at presentation and a change of less than 3 ng/L over the first hour based on the sensitive assay. The sensitivity of this approach was 100% for the rule-out group, supporting the concept that it was safe enough to rule out acute MI. An algorithm, such as this, could reduce patients’ time in the emergency department from 6–8 hours to 1–2 hours.

Finally, other advantages and disadvantages of using the high-sensitivity troponin assay in the emergency department must be considered. For example, early diagnosis of acute MI will allow earlier initiation of anticoagulant and antiplatelet therapy and, potentially, more efficient care. The assay may also improve triaging of patients presenting with chest pain. On the other hand, its lower specificity may result in prolonged hospital stays and the increased use of invasive tests, such as angiography, in patients with normal coronary arteries. Randomized trials comparing the systematic use of the high-sensitivity troponin assay versus the conventional assay in patients presenting with chest pain would be able to determine the potential benefit of early initiation of therapies in terms of clinical outcomes and time to safe discharge from the hospital.

**Limitations**
The multiple analyzers and various cut-off points associated with the high-sensitivity troponin I assay preclude attempts to meta-analyze the data because of significant heterogeneity. The variation in intervals between initial assay and retesting limited our ability to assess the diagnostic accuracy of the high-sensitivity troponin T assay at different times after symptom onset, except at presentation where data were

---

**Figure 2:** Summary receiver operating characteristic curve (bivariable model) for the high-sensitivity troponin T assay for the diagnosis of acute myocardial infarction at presentation, based on meta-analysis of 9 studies.

**Figure 3:** Comparison of receiver operating characteristic curves for the high-sensitivity troponin T assay and the conventional troponin assay for the diagnosis of acute myocardial infarction at presentation. The loops surrounding the filled shapes summarize the 95% confidence regions (CRs) for each test.
available from all trials. Furthermore, the reference standard for acute MI adjudication was a conventional troponin assay, which will eventually underestimate the sensitivity and specificity of the high-sensitivity troponin T assay and overestimate them for the conventional troponin assay. The selected studies also used different conventional troponin assays and cut-off points as a reference standard for acute MI adjudication, and this may be a source of bias. Finally, only English-language studies were included in our analysis; relevant studies in other languages may have been omitted.

### Table 4: Diagnostic performance of high-sensitivity troponin T compared with conventional troponin assay at various times after presentation

<table>
<thead>
<tr>
<th>Study</th>
<th>Early assay, AUC (95% CI)</th>
<th>Later assay, AUC (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reichlin et al. 2009*</td>
<td>0.98 (0.97–0.99)</td>
<td>0.98 (0.96–0.99)</td>
</tr>
<tr>
<td>Reiter et al. 2011†‡</td>
<td>0.97 (0.94–0.99)</td>
<td>0.96 (0.92–0.99)</td>
</tr>
<tr>
<td>Christ et al. 2010</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Aldous et al. 2011</td>
<td>NA</td>
<td>0.94 (0.91–0.97)</td>
</tr>
<tr>
<td>Body et al. 2011</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Freund et al. 2011</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Weber et al. 2011</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Melki et al. 2011</td>
<td>0.99, specificity 0.71</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>PPV 77%, NPV 99%</td>
<td></td>
</tr>
<tr>
<td>Aldous et al. 2012</td>
<td>0.92, specificity 0.80</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>PPV 55.9%, NPV 97.3%</td>
<td></td>
</tr>
</tbody>
</table>

Note: AUC = area under the curve, CI = confidence interval, NA = not available, NPV = negative predictive value, PPV = positive predictive value.

*Older population (≥ 70 yr).

### Table 5: Diagnostic performance of high-sensitivity troponin I versus conventional troponin T assay at presentation

<table>
<thead>
<tr>
<th>Study</th>
<th>High-sensitivity troponin I assay</th>
<th>Conventional troponin T assay</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Cut-off point and assay</td>
<td>Sensitivity</td>
</tr>
<tr>
<td>Reichlin et al. 2009*</td>
<td>40 ng/L ADVIA Centaur Immunoassay System (Siemens)</td>
<td>0.89</td>
</tr>
<tr>
<td>Bhardwaj et al. 2011†‡</td>
<td>6.28 ng/L Erenna Immunoassay System (Singulex)</td>
<td>0.57</td>
</tr>
<tr>
<td>Keller et al. 2009‡‡</td>
<td>40 ng/L Troponin I Ultra (Siemens Healthcare Diagnostics)</td>
<td>0.91</td>
</tr>
</tbody>
</table>

Note: NPV = negative predictive value, PPV = positive predictive value.
Conclusion

For patients presenting to the emergency department, the high-sensitivity assay for cardiac troponin has higher sensitivity but lower specificity than the conventional assay and, thus, may be useful in triaging patients. Over 6 hours, the area under the curve for both high-sensitivity troponin T and conventional troponin assays was similar. Future studies are needed to determine the potential benefits of earlier treatment and the economic consequences of the use of the high-sensitivity assay.

References